Posts

Showing posts with the label cancer

Incredible clinical cause beyond a five-monthold boy's poor feeding include his rapid brain's cognition and preference for certain colors as well as his early experience with those colors: Case Report by Dr.Khajik Sirob Yaqob Qazaryan in Journal of Clinical Case Reports Medical Images and Health Sciences

  Incredible clinical cause beyond a five-monthold boy's poor feeding include his rapid brain's cognition and preference for certain colors as well as his early experience with those colors: Case Report   by Dr.Khajik Sirob Yaqob Qazaryan in  Journal of Clinical Case Reports Medical Images and Health Sciences Abstract  The study's abstract highlights the numerous clinical factors that contribute to a five-month-old boy's malnutrition in addition to inadequate feeding. These factors include color choice, early color vision, and mature brain cognition. Infants normally develop their sense of perception during their first year of life. This article emphasizes how a five-month-old baby can recognize colors, in particular red and blue ones. I also go through how, in very rare instances, the early development of color perception can have a clinical effect on feeding. This essay questions the widely held belief that babies under six months old can only recognize the color...

First line chemotherapy in metastatic colorectal cancers: A review by Alfredo Colombo in Journal of Clinical Case Reports Medical Images and Health Sciences

  First line chemotherapy in metastatic colorectal cancers: A review by Alfredo Colombo in Journal of Clinical Case Reports Medical Images and Health Sciences Abstract   A common malignancy that is detected is colorectal cancer (CRC). Unresectable, metastatic colorectal cancer (mCRC) patients have a poor prognosis and typically receive palliative care. Chemotherapy is the mainstay of therapy, but as molecular biology and its heterogeneity are better understood, the field is evolving. Depending on the clinical patient characteristics and tumor molecular profile, first-line therapy uses a combination of chemotherapy and targeted therapies. In this article, we examine the most recent data from randomized clinical trials supporting the use of chemotherapy triplets or doublets as well as the addition of bevacizumab or anti-epidermal growth factor receptor (EGFR) agents.  Introduction  One of the three cancer killers in developed countries is colorectal cancer (CRC), a ...